TG Therapeutics Reports Positive Data From Umbralisib Trial
TG Therapeutics Inc. (TGTX) reported positive top line data from its Phase 3 trial pertaining to Umbralisib. The trial seeks to evaluate the combination of the drug candidate with ublituximab compared to obinutuzumab plus chlorambucil in subjects suffering from previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL). The trial will be stopped early for superior efficacy.
TG Therapeutics stated that the trial met its primary endpoint which was related to progression-free survival. The interim analysis showed a statistically significant improvement in progression-free survival